Biomarkers and Parkinson's disease

Brain

Volumn 127, Issue 8, 2004, Pages 1693-1705

  Michell, A W ^a   Lewis, S J G ^a   Foltynie, T ^a   Barker, R A ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Biomarkers; Diagnosis; Parkinson's disease

Indexed keywords

(3 IODOBENZYL)GUANIDINE; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2BETA CARBOXYMETHOXY 3BETA (4 IODOPHENYL)TROPANE I 123; 3 HYDROXYTYROSINE F 18; AMINO ACID DECARBOXYLASE; BIOLOGICAL MARKER; COPPER; DEOXYGUANOSINE; DIHYDROTETRABENAZINE C 11; FERRITIN; FLECAINIDE; FLUORODEOXYGLUCOSE F 18; HOMOVANILLIC ACID; IODOBENZAMIDE I 123; IRON; LEVODOPA; MALONALDEHYDE; METHYLPHENIDATE C 11; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL) CYCLOHEXANECARBOXAMIDE C 11; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE C 11; OXIDOREDUCTASE; PRAMIPEXOLE; RACLOPRIDE C 11; RADIOISOTOPE; RNA; ROPINIROLE; SUPEROXIDE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; ZINC;

ACCELEROMETER; ANXIETY; BASAL GANGLION; BLADDER IRRITATION; BLOOD PRESSURE; BLOOD SAMPLING; BRADYKINESIA; BRAIN BLOOD FLOW; BRAIN SCINTISCANNING; CAUDATE NUCLEUS; CELL DAMAGE; CELL LOSS; CEREBROSPINAL FLUID; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; CORRELATION ANALYSIS; DEGENERATIVE DISEASE; DEMENTIA; DEPRESSION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE COURSE; DISEASE MARKER; DISEASE PREDISPOSITION; DNA SEQUENCE; DOPAMINE UPTAKE; DOPAMINERGIC NERVE CELL; DOPPLER ECHOGRAPHY; DRUG EFFICACY; ELECTROMYOGRAM; ELECTRONEUROLOGY; ENZYME ACTIVITY; GENE MUTATION; GENETIC PROCEDURES; GENETIC SCREENING; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; INTROVERSION; LEWY BODY; LINKAGE ANALYSIS; MICROGLIA; MOOD DISORDER; MORTALITY; MOTIVATION; MOTOR PERFORMANCE; MUSCULOSKELETAL DISEASE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; PUTAMEN; QUANTITATIVE ANALYSIS; QUESTIONNAIRE; RADIODIAGNOSIS; RATING SCALE; REVIEW; RISK ASSESSMENT; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMELLING; STROKE; SWEATING; TISSUE SPECIFICITY; TREATMENT OUTCOME; TREMOR; VALIDATION PROCESS; VISUAL ACUITY;

BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; PARKINSON DISEASE; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME;

EID: 4043182789     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/awh198     Document Type: Review

References (149)

1. Abe T, Isobe C, Murata T, Sato C, Tohgi H. Alteration of 8-hydroxyguanosine concentrations in the cerebrospinal fluid and serum from patients with Parkinson's disease. Neurosci Lett 2003; 336: 105-8.
2. Andrews TC, Weeks RA, Turjanski N, Gunn RN, Watkins LH, Sahakian B, et al. Huntington's disease progression. PET and clinical observations. Brain 1999; 122: 2353-63.
3. Antonini A, Leenders KL, Vontobel P, Maguire RP, Missimer J, Psylla M, et al. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain 1997; 120: 2187-95.
4. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-71.
5. Becker G, Berg D. Neuroimaging in basal ganglia disorders: perspectives for transcranial ultrasound. Mov Disord 2001; 16: 23-32.
6. Ben-Shlomo Y, Wenning G. Incidental Lewy body disease. Lancet 1994; 344: 1503.
7. Berendse HW, Booij J, Francot CM, Bergmans PL, Hijman R, Stoof JC, et al. Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell. Ann Neurol 2001; 50: 34-41.
8. Berg D, Becker G, Zeiler B, Tucha O, Hoffmann E, Preier M, et al. Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 1999; 53: 1026-31.
9. Berg D, Jabs B, Merschdorf U, Beckmann H, Becker G. Echogenicity of substantia nigra determined by transcranial ultrasound correlates with severity of parkinsonian symptoms induced by neuroleptic therapy. Biol Psychiatry 2001a; 50: 463-7.
10. Berg D, Siefker C, Becker G. Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. J Neurol 2001b; 248: 684-9.
11. Berg D, Siefker C, Ruprecht-Dorfler P, Becker G. Relationship of substantia nigra echogenicity and motor function in elderly subjects. Neurology 2001c; 56: 13-7.
12. Berg D, Roggendorf W, Schroder U, Klein R, Tatschner T, Benz P, et al. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 2002; 59: 999-1005.
13. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
14. Blin O, Desnuelle C, Rascol O, Borg M, Peyro Saint Paul H, Azulary JP, et al. Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy. J Neurol Sci 1994; 125: 95-101.
15. Bodis-Wollner I, Onofrj M. The visual system in Parkinson's disease. Adv Neurol 1987; 45: 323-7.
16. Bonuccelli U, Piccini P, Del Dotto P, Pacifici GM, Corsini GU, Muratorio A. Platelet monoamine oxidase B activity in parkinsonian patients. J Neurol Neurosurg Psychiatry 1990; 53: 854-5.
17. Borghi R, Marchese R, Negro A, Marinelli L, Forloni G, Zaccheo D, et al. Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci Lett 2000; 287: 65-7.
18. Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rub U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol 2002; 249 Suppl 3: III/1-III/5.
19. Braune S. The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes. Clin Auton Res 2001; 11: 351-5.
20. Briand KA, Strallow D, Hening W, Poizner H, Sereno AB. Control of voluntary and reflexive saccades in Parkinson's disease. Exp Brain Res 1999; 129: 38-48.
21. Brindle JT, Antti H, Holmes E, Tranter G, Nicholson JK, Bethell HW, et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med 2002; 8: 1439-44.
22. Brooks DJ. Imaging end points for monitoring neuroprotection in Parkinson's disease. Ann Neurol 2003; 53 Suppl 3: S110-S118.
23. Brooks DJ, Ibanez V, Sawle GV, Playford ED, Quinn N, Mathias CJ, et al. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Ann Neurol 1992; 31: 184-92.
24. Brooks DJ, Frey KA, Marek KL, Playford ED, Quinn N, Prentice R, et al. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp Neurol 2003; 184 Suppl 1: S68-S79.
25. Brown RG, Soliveri P, Jahanshahi M. Executive processes in Parkinson's disease-random number generation and response suppression. Neuropsychologia 1998; 36: 1355-62.
26. Brucke T, Djamshidian S, Bencsits G, Pirker W, Asenbaum S, Podreka I. SPECT and PET imaging of the dopaminergic system in Parkinson's disease. J Neurol 2000; 247 Suppl 4: IV/20-7.
27. Burn DJ, Lees AJ. Progressive supranuclear palsy: where are we now? Lancet Neurol 2002; 1: 359-69.
28. Burn DJ, Mark MH, Playford ED, Maragonore DM, Zimmermann TR Jr, Duvoisin RC, et al. Parkinson's disease in twins studied with 18F-dopa and positron emission tomography. Neurology 1992; 42: 1894-900.
29. Burn DJ, Sawle GV, Brooks DJ. Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. J Neurol Neurosurg Psychiatry 1994; 57: 278-84.
30. Buttner T, Kuhn W, Muller T, Patzold T, Heidbrink K, Przuntek H. Distorted color discrimination in 'de novo' parkinsonian patients. Neurology 1995; 45: 386-7.
31. Calne DB, Langston JW, Martin WR, Stoessl AJ, Ruth TJ, Adam MJ, et al. Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease. Nature 1985; 317: 246-8.
32. Caronti B, Antonini G, Calderaro C, Ruggieri S, Palladini G, Pontieri FE, et al. Dopamine transporter immunoreactivity in peripheral blood lymphocytes in Parkinson's disease. J Neural Transm 2001; 108: 803-7.
33. Cicchetti F, Brownell AL, Williams K, Chen YI, Livni E, Isacson O. Neuro-inflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci. 2002; 15: 991-8.
34. Cooper JA, Sagar HJ, Jordan N, Harvey NS, Sullivan EV. Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability. Brain 1991; 114: 2095-122.
35. Cowles MK. Bayesian estimation of the proportion of treatment effect captured by a surrogate marker. Stat Med 2002; 21: 811-34.
36. Da Prada M, Cesura AM, Launay JM, Richards JG. Platelets as a model for neurones? Experientia 1988; 44: 115-26.
37. Dekker MC, Bonifati V, van Duijn CM. Parkinson's disease: piecing together a genetic jigsaw. Brain 2003; 126: 1722-33.
38. Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ. Tremor in Parkinson's disease and serotonergic dysfunction: an (11)C-WAY 100635 PET study. Neurology 2003; 60: 601-5.
39. Doty RL, Golbe LI, McKeown DA, Stern MB, Lehrach CM, Crawford D. Olfactory testing differentiates between progressive supranuclear palsy and idiopathic Parkinson's disease. Neurology 1993; 43: 962-5.
40. Drouot X, Moutereau S, Nguyen JP, Peters RW, Lefaucher JP, Creange A, Remy P, et al. Low levels of ventricular CSF orexin/hypocretin in advanced PD. Neurology 2003; 61: 540-3.
41. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324: 781-8.
42. Eidelberg D, Takikawa S, Moeller JR, Dhawan V, Redington K, Chaly T, et al. Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's disease. Ann Neurol 1993; 33: 518-27.
43. Fahn S. Results of the ELLDOPA (Earlier vs. later Levodopa) study. Mov Disord 2002; 17: S13-S14.
44. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991; 114: 2283-301.
45. Filipovic SR, Sternic N, Sveiel M, Dragasevic N, Lecic D, Kostic VS. Bereitschaftspotential in depressed and non-depressed patients with Parkinson's disease. Mov Disord 2001; 16: 294-300.
46. Foltynie T, Brayne C, Barker RA. The heterogeneity of idiopathic Parkinson's disease. J Neurol 2002a; 249: 138-45.
47. Foltynie T, Sawcer S, Brayne C, Barker RA. The genetic basis of Parkinson's disease. J Neurol Neurosurg Psychiatry 2002b; 73: 363-70.
48. Foltynie T, Brayne CE, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain 2004; 127: 550-60.
49. Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001; 344: 710-9.
50. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, et al. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 2002; 4: 160-4.
51. Calvin JE, Lee VM, Trojanowski JQ. Synucleinopathies: clinical and pathological implications. Arch Neurol 2001; 58: 186-90.
52. Gerhard A, Banati RB, Goerres GB, Cagnin A, Myers R, Gunn RN, et al. [(11)C](R)-PK11195 PET imaging of microglial activation in multiple system atrophy. Neurology 2003; 61: 686-9.
53. Giladi N, Simon ES, Korczyn AD, Groozman GB, Orlov Y, Shabtai H, et al. Anal sphincter EMG does not distinguish between multiple system atrophy and Parkinson's disease. Muscle Nerve 2000; 23: 731-4.
54. Gonera EG, van't Hof M, Berger HJ, van Weel C, Horstink MW. Symptoms and duration of the prodromal phase in Parkinson's disease. Mov Disord 1997; 12: 871-6.
55. Gotz ME, Gerstner A, Harth R, Dirr A, Janetzky B, Kuhn W, et al. Altered redox state of platelet coenzyme Q10 in Parkinson's disease. J Neural Transm 2000; 107: 41-8.
56. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-62.
57. Hartikainen P, Reinikainen KJ, Soininen H, Sirvio J, Soikkeli R, Riekkinen PJ. Neurochemical markers in the cerebrospinal fluid of patients with Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis and normal controls. J Neural Transm Park Dis Dement Sect 1992; 4: 53-68.
58. Hashimoto M, Yoshimoto M, Sisk A, Hsu LJ, Sundsmo M, Kittel A, et al. NACP, a synaptic protein involved in Alzheimer's disease, is differentially regulated during megakaryocyte differentiation. Biochem Biophys Res Commun 1997; 237: 611-6.
59. Hawkes C. Olfaction in neurodegenerative disorder. Mov Disord 2003; 18: 364-72.
60. Hilker R, Klein C, Hedrich K, Ozelius LJ, Vieregge P, Herholz K, et al. The striatal dopaminergic deficit is dependent on the number of mutant alleles in a family with mutations in the parkin gene: evidence for enzymatic parkin function in humans. Neurosci Lett 2002; 323: 50-4.
61. Hocherman S, Giladi N. Visuomotor control abnormalities in patients with unilateral parkinsonism. Neurology 1998; 50: 1648-54.
62. Holthoff VA, Vieregge P, Kessler J, Pietrzyk U, Herholz K, Bonner J, et al. Discordant twins with Parkinson's disease: positron emission tomography and early signs of impaired cognitive circuits. Ann Neurol 1994; 36: 176-82.
63. Hoogendijk WJ, Sommer IE, Tissingh G, Deeg DJ, Wolters EC. Depression in Parkinson's disease. The impact of symptom overlap on prevalence. Psychosomatics 1998; 39: 416-21.
64. Horstink MW, Morrish PK. Preclinical diagnosis of Parkinson's disease. Adv Neurol 1999; 80: 327-33.
65. Huber SJ, Freidenberg DL, Paulson GW, Shuttleworth EC, Christy JA. The pattern of depressive symptoms varies with progression of Parkinson's disease. J Neurol Neurosurg Psychiatry 1990; 53: 275-8.
66. Hughes AJ, Ben Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992; 42: 1142-6.
67. Hughes AJ, Daniel SE, Ben Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002; 125: 861-70.
68. Ilic TV, Jovanovic M, Jovicic A, Tomovic M. Oxidative stress indicators are elevated in de novo Parkinson's disease patients. Funct Neurol 1999; 14: 141-7.
69. International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 1991; 324: 509-16.
70. Jenner P. Presymptomatic detection of Parkinson's disease. J Neural Transm Suppl 1993; 40: 23-36.
71. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003; 53 Suppl 3: S26-S36.
72. Jimenez-Jimenez FJ, Molina JA, Vargas C, Gomez P, De Bustos F, Zurdo M, et al. Normal cerebrospinal fluid levels of insulin in patients with Parkinson's disease. J Neural Transm 2000; 107: 445-9.
73. Kikuchi A, Takeda A, Onodera H, Kimpara T, Hisanaga K, Sato N, et al. Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy. Neurobiol Dis 2002; 9: 244-8.
74. Kitada T, Asakawa S, Hattori N, Matsumina H, Yamamura Y, Minoshima S, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392: 605-8.
75. Kraus PH, Przuntek H, Kegelmann A, Klotz P. Motor performance: normative data, age dependence and handedness. J Neural Transm 2000; 107: 73-85.
76. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998; 18: 106-8.
77. Laihinen A, Ruottinen H, Rinne JO, Haaparanta M, Bergman J, Solim O, et al. Risk for Parkinson's disease: twin studies for the detection of asymptomatic subjects using [18F]6-fluorodopa PET. J Neurol 2000; 247 Suppl 2: 11110-11113.
78. Lawrence AD, Hodges JR, Rosser AE, Kershaw A, ffrench-Constant C, Rubinsztein DC, et al. Evidence for specific cognitive deficits in preclinical Huntington's disease. Brain 1998; 121: 1329-41.
79. Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, Holden JE, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 2000; 47: 493-503.
80. Lewis GN, Byblow WD. Altered sensorimotor integration in Parkinson's disease. Brain 2002; 125: 2089-99.
81. Lewis SJ, Cools R, Robbins TW, Dove A, Barker RA, Owen AM. Using executive heterogeneity to explore the nature of working memory deficits in Parkinson's disease. Neuropsychologia 2003a; 41: 645-54.
82. Lewis SJ, Dove A, Robbins TW, Barker RA, Owen AM. Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry. J Neurosci 2003b; 23: 6351-6.
83. LeWitt PA, Galloway MP, Matson W, Milbury P, McDermott M, Srivastava DK, et al. Markers of dopamine metabolism in Parkinson's disease. The Parkinson Study Group. Neurology 1992; 42: 2111-7.
84. Li QX, Campbell BC, McLean CA, Thyagarajan D, Gai WP, Kapsa RM, et al. Platelet alpha- and gamma-synucleins in Parkinson's disease and normal control subjects. J Alzheimers Dis 2002; 4: 309-15.
85. Libelius R, Johansson F. Quantitative electromyography of the external anal sphincter in Parkinson's disease and multiple system atrophy. Muscle Nerve 2000; 23: 1250-6.
86. Loeffler DA, LeWitt PA, DeMaggio AJ, Juneau PL, Milbury PE, Matson WR. Markers of dopamine depletion and compensatory response in striatum and cerebrospinal fluid. J Neural Transm Park Dis Dement Sect 1995; 9: 45-53.
87. Mann VM, Cooper JM, Krige D, Daniel SE, Schapira AH, Marsden CD. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. Brain 1992; 115: 333-42.
88. Marder K, Tang MX, Mejia H, Alfaro B, Cote L, Louis E et al. Risk of Parkinson's disease among first-degree relatives: A community-based study. Neurology 1996; 47: 155-60.
89. Marek K, Innis R, van Dyck C, Fussell B, Early M, Eberly S, et al. [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 2001; 57: 2089-94.
90. Martinez-Martin P, Gil-Nagel A, Gracia LM, Gomez JB, Martinez-Sarries J, Bermejo F. Unified Parkinson's Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group. Mov Disord 1994; 9: 76-83.
91. Menza M. The personality associated with Parkinson's disease. Curr Psychiatry Rep 2000; 2: 421-6.
92. Montgomery EB Jr, Koller WC, LaMantia TJ, Newman MC, Swanson-Hyland E, Kaszniak AW, et al. Early detection of probable idiopathic Parkinson's disease: I. Development of a diagnostic test battery. Mov Disord 2000a; 15: 467-73.
93. Montgomery EB Jr, Lyons K, Koller WC. Early detection of probable idiopathic Parkinson's disease: II. A prospective application of a diagnostic test battery. Mov Disord 2000b; 15: 474-8.
94. Morrish PK. How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson's disease? Mov Disord 2003; 18 Suppl 7: S63-S70.
95. Morrish PK, Sawle GV, Brooks DJ. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996a; 119: 585-91.
96. Morrish PK, Sawle GV, Brooks DJ. Regional changes in [18F]dopa metabolism in the striatum in Parkinson's disease. Brain 1996b; 119: 2097-103.
97. Muller A, Reichmann H, Livermore A, Hummel T. Olfactory function in idiopathic Parkinson's disease (IPD): results from cross-sectional studies in IPD patients and long-term follow-up of de-novo IPD patients. J Neural Transm 2002; 109: 805-11.
98. Nutt JG, Carter JH, Lea ES, Sexton GJ. Evolution of the response to levodopa during the first 4 years of therapy. Ann Neurol 2002; 51: 686-93.
99. O'Neill J, Schuff N, Marks WJ Jr, Feiwell R, Aminoff MJ, Weiner MW. Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease. Mov Disord 2002; 17: 917-27.
100. Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003; 54: 403-14.
101. Owen AM, James M, Leigh PN, Summers BA, Marsden CD, Quinn NP, et al. Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain 1992; 115: 1727-51.
102. Parker WD Jr, Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 1989; 26: 719-23.
103. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. JAMA 2000; 284: 1931-8.
104. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002; 287: 1653-61.
105. Pate BD, Kawamata T, Yamada T, McGeer EG, Hewitt KA, Snow BJ, et al. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann Neurol 1993; 34: 331-8.
106. Payami H, Larsen K, Bernard S, Nutt J. Increased risk of Parkinson's disease in parents and siblings of patients. Ann Neurol 1994; 36: 659-61.
107. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.
108. Piccini P, Morrish PK, Turjanski N, Sawle GV, Burn DJ, Weeks RA, et al. Dopaminergic function in familial Parkinson's disease: a clinical and 18F-dopa positron emission tomography study. Ann Neurol 1997; 41: 222-9.
109. Piccini P, Brooks DJ, Bjorklund A, Gunn RN, Grasby PM, Rimoldi O, et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci 1999a; 2: 1137-40.
110. Piccini P, Burn DJ, Ceravolo R, Maraganore D, Brooks DJ. The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol 1999b; 45: 577-82.
111. Poewe W, Wenning G. The differential diagnosis of Parkinson's disease. Eur J Neurol 2002; 9 Suppl 3: 23-30.
112. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276: 2045-7.
113. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989; 8: 431-40.
114. Price MJ, Feldman RG, Adelberg D, Kayne H. Abnormalities in color vision and contrast sensitivity in Parkinson's disease. Neurology 1992; 42: 887-90.
115. Qualman SJ, Haupt HM, Yang P, Hamilton SR. Esophageal Lewy bodies associated with ganglion cell loss in achalasia. Similarity to Parkinson's disease. Gastroenterology 1984; 87: 848-56.
116. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism - a prospective study. Can J Neurol Sci 1991; 18: 275-8.
117. Rivner MH. Statistical errors and their effect on electrodiagnostic medicine. Muscle Nerve 1994; 17: 811-814.
118. Rossini PM, Babiloni F, Bernardi G, Cecchi L, Johnson PB, Malentacca A, et al. Abnormalities of short-latency somatosensory evoked potentials in parkinsonian patients. Electroencephalogr Clin Neurophysiol 1989; 74: 277-89.
119. Savoiardo M. Differential diagnosis of Parkinson's disease and atypical parkinsonian disorders by magnetic resonance imaging. Neurol Sci 2003; 24 Suppl 1: S35-S37.
120. Sawle GV, Playford ED, Burn DJ, Cunningham VJ, Brooks DJ. Separating Parkinson's disease from normality. Discriminant function analysis of fluorodopa F 18 positron emission tomography data. Arch Neurol 1994; 51: 237-43.
121. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994; 344: 1383-9.
122. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 1990; 54: 823-7.
123. Schneider JS, Pope-Coleman A. Cognitive deficits precede motor deficits in a slowly progressing model of parkinsonism in the monkey. Neurodegeneration 1995; 4: 245-55.
124. Schulzer M. Diagnostic tests: a statistical review. Muscle Nerve 1994; 17: 815-9.
125. Schwarz J, Linke R, Kerner M, Mozley PD, Trenkwalder C, Gasser T, et al. Striatal dopamine transporter binding assessed by [I-123]IPT and single photon emission computed tomography in patients with early Parkinson's disease: implications for a preclinical diagnosis. Arch Neurol 2000; 57: 205-8.
126. Singaram C, Ashraf W, Gaumnitz EA, Torbey C, Sengupta A, Pfeiffer R, et al. Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation. Lancet 1995; 346: 861-4.
127. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus H, et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003; 302: 841.
128. Snow BJ, Tooyama I, McGeer EG, Yamada T, Calne DB, Takahashi H, et al. Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 1993; 34: 324-30.
129. Stocchi F, Olanow CW. Neuroprotection in Parkinson's disease: clinical trials. Ann Neurol 2003; 53 Suppl 3: S87-S97.
130. Sveinbjornsdottir S, Hicks AA, Jonsson T, Petursson H, Gugmundsson G, Frigge ML, et al. Familial aggregation of Parkinson's disease in Iceland. N Engl J Med 2000; 343: 1765-70.
131. Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, Mayeux R, et al. Parkinson disease in twins: an etiologic sludy. JAMA 1999; 281: 341-6.
132. Temple R. Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA 1999; 282: 790-5.
133. Tissingh G, Berendse HW, Bergmans P, DeWaard R, Drukarch B, Stoof JC, et al. Loss of olfaction in de novo and treated Parkinson's disease: possible implications for early diagnosis. Mov Disord 2001; 16: 41-6.
134. Todes CJ, Lees AJ. The pre-morbid personality of patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1985; 48: 97-100.
135. Valls-Sole J, Valldeoriola F. Neurophysiological correlate of clinical signs in Parkinson's disease. Clin Neurophysiol 2002; 113: 792-805.
136. Vesela O, Ruzicka E, Jech R, Roth J, Stepankova K, Mecir P, et al. Colour discrimination impairment is not a reliable early marker of Parkinson's disease. J Neurol 2001; 248: 975-8.
137. Vodusek DB. Sphincter EMG and differential diagnosis of multiple system atrophy. Mov Disord 2001; 16: 600-7.
138. Wakabayashi K, Takahashi H. Neuropathology of autonomic nervous system in Parkinson's disease. Eur Neurol 1997; 38 Suppl 2: 2-7.
139. Walter U, Wittstock M, Benecke R, Dressler D. Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson's disease. J Neural Transm 2002; 109: 191-6.
140. Warner TT, Schapira AH. Genetic and environmental factors in the cause of Parkinson's disease. Ann Neurol 2003; 53 Suppl 3: S16-S23.
141. Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003; 54: 93-101.
142. Wolters EC, Francot C, Bergmans P, Winogrodzka A, Booij J, Berendse HW, et al. Preclinical (premotor) Parkinson's disease. J Neurol 2000; 247 Suppl 2: II103-II109.
143. Yekhlef F, Ballan G, Macia F, Delmer O, Sourgen C, Tison F. Routine MRI for the differential diagnosis of Parkinson's disease, MSA, PSP, and CBD. J Neural Transm 2003; 110: 151-69.
144. Yoshita M, Taki J, Yamada M. A clinical role for [(123)I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer's-type and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2001; 71: 583-8.
145. Zakrzewska-Pniewska B, Jamrozik Z. Are electrophysiological autonomic tests useful in the assessment of dysautonomia in Parkinson's disease? Parkinsonism Relat Disord 2003; 9: 179-83.
146. Zhou G, Shoji H, Yamada S, Matsuishi T. Decreased beta-phenylethylamine in CSF in Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 63: 754-58.
147. Zhou G, Miura Y, Shoji H, Yamada S, Matsuishi T. Platelet monoamine oxidase B and plasma beta-phenylethylamine in Parkinson's disease. J Neurol Neurosurg Psychiatry 2001; 70: 229-31.
148. Zhuang ZP, Kung MP, Hou C, Plossl K, Skoronsky D, Gur TL, et al. IBOX(2-(4′-dimethylaminophenyl)-6-iodobenzoxazole): a ligand for imaging amyloid plaques in the brain. Nucl Med Biol 2001; 28: 887-94.
149. Zigmond MJ, Hastings TG, Perez RG. Increased dopamine turnover after partial loss of dopaminergic neurons: compensation or toxicity? Parkinsonism Relat Disord 2002; 8: 389-93.